Lanxess Deutschland GmbH and NRW.BANK Venture Fonds II have acquired an equity participation in evocatal GmbH, Düsseldorf. Network Corporate Finance exclusively advised evocatal GmbH on this transaction.

#Key data

Industry: Healthcare
Project type:
Description: Growth financing
Date: May 2013


The growth funds will primarily be used to broaden the product range, to internationalise sales & distribution channels and to increase production capacities.


The Company 

evocatal GmbH develops and produces technical enzymes and fine chemicals for the chemical and pharmaceutical industries. Its proprietary enzymes and biocatalytic processes position the company as innovation partner and catalyst of the paradigm shift towards a resource-efficient, bio-based economy.

For additional information on evocatal GmbH please visit:

< Back to overview